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Hippocampal sclerosis in epilepsy: a neuropathology review
Hippocampal sclerosis (HS) is a common pathology
encountered in mesial temporal lobe epilepsy (MTLE) as
well as other epilepsy syndromes and in both surgical
and post-mortem practice. The 2013 International
League Against Epilepsy (ILAE) classification segregates
HS into typical (type 1) and atypical (type 2 and 3)
groups, based on the histological patterns of subfield
neuronal loss and gliosis. In addition, granule cell reor-
ganization and alterations of interneuronal populations,
neuropeptide fibre networks and mossy fibre sprouting
are distinctive features of HS associated with epilepsies;
they can be useful diagnostic aids to discriminate from
other causes of HS, as well as highlighting potential
mechanisms of hippocampal epileptogenesis. The cause
of HS remains elusive and may be multifactorial; the
contribution of febrile seizures, genetic susceptibility,
inflammatory and neurodevelopmental factors are dis-
cussed. Post-mortem based research in HS, as an addition
to studies on surgical samples, has the added advantage
of enabling the study of the wider network changes asso-
ciated with HS, the long-term effects of epilepsy on
the pathology and associated comorbidities. It is likely
that HS is heterogeneous in aspects of its cause,
epileptogenetic mechanisms, network alterations and
response to medical and surgical treatments. Future
neuropathological studies will contribute to better recog-
nition and understanding of these clinical and patho-
aetiological subtypes of HS.
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Introduction
The hippocampus is the most widely studied brain region
in both human and experimental epilepsy. Sclerosis of the
hippocampus in epilepsy was first noted as far back as
1825 [1] followed by the first detailed study of the seg-
mental patterns of neuronal loss in a series of 90 post-
mortem (PM) cases, published by Sommer in 1880 ([2], for
historical review see [3]). In the modern era of epilepsy
surgical programmes for the management of drug-
resistant epilepsy, hippocampal sclerosis (HS) is one of the
commonest pathologies [4]. HS is particularly associated
with the syndrome of mesial temporal lobe epilepsy
(MTLE) but can be seen at PM in other epilepsy syn-
dromes. It’s incidence in large epilepsy surgical series
varies from 33.6% [5] to 66% [6] and in PM series, HS is
identified in between 30.5% and 45% of all epilepsy syn-
dromes and in 56% with the syndrome of MTLE [7,8].
Neuropathology research in MTLE/HS has been based
largely on human surgical tissues, often in parallel with
observations in the numerous experimental models of
temporal lobe epilepsy (TLE). It has been directed into
causes of HS, the cellular and molecular alterations that
render the hippocampus epileptogenic, the identification
of biomarkers that could be predictive of outcome follow-
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ing surgery as well as correlation with other comorbidities
associated with seizures. This review aims to summarize
some of the recent advances in this field which may be of
relevance to the diagnostic neuropathologist.
HS criteria, classification and patterns
There have been several schemes to classify subtypes of
HS, based on the subfield distribution as well as extent of,
hippocampal neuronal loss and gliosis. Other terms used
interchangeably for HS include Ammon’s Horn sclerosis
(strictly refers to neuronal loss in CA1–4 and not the
dentate gyrus) and mesial temporal sclerosis (which
implies more extended sclerosis of extrahippocampal
tissues, such as the amygdala and parahippocampal
gyrus). A recent consensus classification system, validated
through the neuropathology taskforce of the Interna-
tional League Against Epilepsy (ILAE) [9], aims to incor-
porate aspects of all previous schemes [10–15] (Table 1),
through implementing a reproducible, semiquantitative
scale for hippocampal subfield neuronal loss. The main
advantages of the ILAE system is that it is based on stand-
ard stains (Table 2), so can be universally adopted in any
centre, it clearly segregates ‘atypical’ (type 2 and 3) from
‘classical’ HS (type 1) and will reduce over-interpretation
of endplate gliosis alone as HS. This new classification
relies on patterns of neuronal loss and gliosis as objective
measures of sclerosis and does not incorporate other
alterations (e.g. mossy fibre sprouting, interneuronal
alterations – see below) which may be more difficult to
reproduce between laboratories. The obvious benefits of a
single system is that it will enable comparisons of data sets
between centres and emergence of accurate pathological
and electroclinical correlations as well as with advanced
magnetic resonance imaging (MRI) sequences [19]. At
present, for example, there is some evidence that HS pat-
terns could be predictive of seizure history or outcome (as
detailed in Table 2); the atypical HS patterns have been
associated with poorer seizure-free outcomes [11]. There
is no evidence to support the proposal that type 2 and 3
evolve to type 1 HS over time. Implementation of this clear
framework over the next years, integrated with clinical,
genetic and imaging data will enable these issues to be
addressed and clearer characterization of different sub-
types of medial TLE with distinct aetiologies, network
alterations and prognosis, in particular the likelihood of a
long-term seizure-free outcome following surgical
removal [20].
The histological hallmarks of HS have long been re-
cognized since the earliest PM and surgical series [2,21].
Distinctive histological features, which may aid in
the discrimination from other causes of HS (e.g.
neurodegeneration or hypoxia-ischaemia) include the
sharp cut-off between the sclerotic CA1 and the spared
neurones of the subiculum (Figure 1A–C), the typical
fibrous, contracted gliosis of CA1 (attesting to the chronic-
ity), granule cell dispersion (GCD) (Figure 1D,E), and scat-
tered hypertrophic neurones (particularly in CA4)
(Figure 1F) with cytoplasmic distention by microtubules
and neurofilaments and increased dendritic complexity
[22,23] (see Table 3). The diagnostic confirmation of HS
relies to some extent on the provision by the surgeon of
‘en-bloc’ resections where the hippocampal subfield conti-
nuity is intact. In small, fragmented or poorly orientated
specimens, confirmation of HS can be challenging [19],
but supported through implementation of a small panel of
special stains (Table 2). In anterior temporal lobectomy
surgical procedures, an average 2 cm of the hippocampal
body is resected [27,28].The pattern of sclerosis tends to be
uniform along the longitudinal axis within a single surgi-
cal specimen in MTLE/HS [18] although variability, in the
extent (Figure 1G–J) or distribution of subfield neuronal
loss is occasionally seen; for example the pattern may rep-
resent type 1 HS at one coronal level and type 2 HS in
another. The clinical significance of patchy vs. complete
subfield damage in resected specimens is, as yet, uncertain
[9].
Granule cell dispersion (GCD)
Although there is no agreed definition for GCD in HS
(granule cell layer thickness >10 cells [29] or 120 μm
[30] have both been proposed), it is a common and strik-
ing feature in 40–50% of cases [29,31]. The extent, as
well as pattern of GCD, including ‘bi-laminar’ patterns or
clusters of granule cells in the molecular layer (Figure 1E),
may vary within cases and alternate with regions of
granule cell loss. Extensive GCD is virtually pathogno-
monic of seizure-induced hippocampal changes and is
typically seen in the context of hippocampal neuronal
loss, particularly of CA4 [13,32], suggesting that is an
acquired process rather than a pre-existing abnormality.
There is evidence linking the presence of GCD with early
onset of epilepsy and febrile seizures (<4 years) as well
as longer duration of epilepsy [31]. There is conflicting
data regarding whether GCD signifies a good outcome
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following surgery [13,31,32].There has been considerable
interest in granule cell reorganization in HS from the per-
spective of its potential contribution to pro-epileptogenic
circuitry, reflection of interference with ongoing
neurogenesis and correlation with memory disorders
associated with epilepsy.
Neuronal migration during development is normally
associated with immature neurones. There are two
schools of thought in HS: that GCD represents neuronal
‘heterotopia’ of newly generated neurones following aber-
rant neurogenesis or that it results from abnormal migra-
tion of mature neurones, both influenced by seizures.
Table 2. Panel of stains useful in the interpretation of HS in epilepsy; those shown in bold are used in the 2013 ILAE classification of HS
[9]
Histological
preparation Application Methods/technical tips, limitation and pitfalls
Luxol fast blue/
cresyl violet
Assessment of neuronal loss; these stains may be used
interchangeably.
NeuN is preferable for assessment of GCD.
Neurofilament can highlight additional neuronal
hypertrophy in CA4.
Synaptophysin has also been used in the assessment of
MFS, but it is not specific for mossy fibre pathway
NeuN is fixation sensitive and gives less consistent
staining in post-mortem tissues*
Thicker sections (>10 μm ) also recommended for
assessment of cyto-architecture with NeuN
NeuN
Synaptophysin
Map2
Neurofilament
GFAP Assessment of gliosis, patterns and distribution Over-interpretation of endplate gliosis as sclerosis
GFAP-delta
CD34
Timm method [16] Assessment of mossy fibre re-organization Timm stain: requires fixation of hippocampal slice from
fresh specimen in buffered 1.2% sodium sulphide
solution
Dynorphin
ZnT3
Dynorphin: Thicker sections (>10 μm) recommended for
better visualization of MFS
Parvalbumin Assessment of interneuronal groups. Antibody clones
used in illustrations in current paper: calbindin D-28K
(1:10 000, Swant, Switzerland )
Calretinin (polyclonal, 1:2000; Sigma, Saint Louis, MO,
USA)
NPY ( 1:4000, Sigma)
Parvalbumin, (1:300 Swant, Switzerland)
Parvalbumin can be fixation sensitive and give less
consistent staining in post-mortem tissues*Calbindin
Calretinin
Neuropeptide
Y (NPY)
*In post-mortem tissues, some markers may be fixation sensitive, for example parvalbumin, NeuN, requiring modified pretreatments [17]; for
Timm method in surgical tissues see [18].
HS, hippocampal sclerosis; GCD, granule cell dispersion; MFS, mossy fibre sprouting; ZnT3, zinc transporter 3.
Table 3. Neuropathological features that may aid in the distinction of hippocampal sclerosis in epilepsy (HS-e) from other cause of HS
[24–26]
Histopathological features predictive of HS-e
Highly associated HS-e Not-predictive Less likely HS-e
Dense fibrillary gliosis in CA1
CA4 neuronal loss
Sharp demarcation between neuronal loss
and gliosis in CA1 and the subiculum
Granule cell dispersion
Mossy fibre sprouting
Interneuronal network reorganization
Hypertrophic (NF-positive) neurones in
CA4 (and other subfields)
CA2 sparing
Neuronal loss and gliosis in CA1 is focal
and not affecting all the subfield
Variability of HS sclerosis along the
longitudinal axis
Bilateral HS
Loss of calbindin expression in granule
cells
Microglial activation
Patchy, widespread cellular ‘reactive’
gliosis; less subfield restricted
Neuronal loss in CA1 extends into
subiculum
Non-subfield specific distribution of
neuronal loss
Identification of neuronal inclusions
with IHC (e.g. Tau, p62 and TDP43)
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Figure 1. Typical pathology features of hippocampal sclerosis in epilepsy. (A) Luxol fast blue/cresyl violet-stained preparation of a surgical
sample with subfield neuronal loss involving CA1 and CA4. (B) GFAP preparation confirming dense fibrillary gliosis in CA1 with a sharp
cut-off point (arrows) with the adjacent subiculum (SBC) and (C) higher magnification detail of the abrupt transition of gliosis at the
CA1/subiculum (arrows). (D) Granule cell dispersion as seen with cresyl violet and (E) with NeuN showing clusters of dispersed granule cells
(inset shows reelin-positive interneurones and bipolar cells in the molecular layer). (F) Neurofilament-positive neurones with enlarged cell
bodies in CA4 of the sclerotic hippocampus. (G) CA1 pyramidal cell layer in a patient with MTLE but no evidence of neuronal loss, (H) CA1
with evidence of partial neuronal loss from mid zone and, (I) CA1 with severe neuronal depletion and collapse of the layer. (J) Section of the
pes hippocampus from a patients with confirmed classical ILAE type 1 sclerosis in the body; in the pes neuronal loss is limited to the endplate
in this case as an illustration of variability in the pattern of atrophy that may occur along the longitudinal hippocampal axis. Bar is
equivalent to approximately 1 mm (A, B, J), 250 micrometers (C, F, G, H, I) and 100 micrometers (D, E).
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There is abundant evidence from experimental models
that seizures influence rates of granule cell neurogenesis,
with new neurones migrating to abnormal or ectopic posi-
tions and furthermore integrating into networks and
acquiring pro-epileptogenic physiological properties [33–
38]. A model of febrile seizures recently reported that
altered migration of newly generated granule cells was
enhanced by excitatory gamma-aminobutyric acid
(GABA) signalling during seizures [39]. In contrast, fol-
lowing kainic acid-induced seizures, time-lapse studies
argue for dispersion of fully differentiated granule cells
[40], migrating by a process of ‘somatic translocation’, a
mechanism which involves shifting of the cell body into an
apical dendrite [41].
It has proven more difficult to explore and validate any
altered rates of neurogenesis or the migratory mechanisms
that have contributed to GCD inTLE at the ‘end stage’ of the
disease process, in either surgical or PM tissues [42–44].
Morphological studies of dispersed cells in HS tissues have
confirmed wider branching angles of the apical dendrites
and more frequent recurrent basal dendrites, which could
support that somatic translocation had occurred [45].
Local deficiency of reelin protein and loss of reelin-
expressing cells has been implicated as orchestrating the
process of GCD (Figure 1E) [40,46,47]. Studies of
calbindin expression patterns, a marker of granule cell
maturity, have also demonstrated differential expression in
the dentate gyrus in HS with more dispersed cells calbindin
positive, while more basal cells are calbindin negative; one
interpretation of this is that a neo-migration of mature
granule cell neurones has occurred [48–52] (Figure 2A–
C). Important clinicopathological correlations include that
a reduction of calbindin-positive granule cells [53], loss of
granule cells in the internal limb of the dentate gyrus [54]
as well as loss of regenerative capacity have all been asso-
ciated with memory impairment arising in association
with TLE [55]. This highlights the important contribution
of granule cell pathology to comorbidities in epilepsy.
Neuropathology studies of epileptogenic
processes in HS
The term epileptogenesis encompasses the cascade of cellu-
lar events, following which a brain develops spontaneous
seizures or epilepsy. There are obvious limitations and
challenges in exploring these processes in human tissues
of HS, usually at an advanced stage and subjected to the
effects of anti-epileptic drugs. The obvious question has
always been how a region with such dramatic depletion of
neurones can generate seizure activity. It is plausible that
the pro-epileptogenic pathophysiological mechanisms are
separate from the sclerosing process. Nevertheless, there
has been a valuable contribution from neuropathological
studies of altered neuronal networks and connectivity
that could underpin hippocampal hyper-excitability to
parallel observed altered neuronal electrophysiological
properties in slice cultures [56]. Furthermore, unravelling
the key epileptogenic events is an essential pathway
towards identifying novel molecular therapeutic targets to
intervene with these processes [57,58].
Mossy fibre sprouting
Axonal sprouting, a common process in the developing
brain, is revived in adult tissues in response to seizures.
Such plasticity may represent primarily a reparative
response to hippocampal neuronal loss, but may ulti-
mately be mal-adaptive and pro-epileptogenic [59]. The
mossy fibre pathway has been most widely studied in this
respect. First observed in animal models, and subse-
quently in human HS [60], mossy fibre sprouting has been
argued a critical component in the development of recur-
rent seizures in HS. In normal conditions, fewer than 1%
of mossy fibres possess a recurrent axonal branch into the
molecular layer but, in HS, extensive recurrent projection
of mossy fibre collaterals into the molecular layer of the
dentate gyrus occurs, to make excitatory synaptic contact
[61] with apical dendrites and spines of granule cells in
the inner molecular layer, essentially creating a local
‘short-circuit’ with a potential to synchronize neuronal
groups. In tissues, mossy fibre sprouting is best demon-
strated with Timm silver method (reaction with zinc,
sequestered in synaptic vesicles) (Figure 2A–C) (Table 2),
zinc transporter 3 [16,62] or with immunohistochemistry
for dynorphin A (an opioid neuropeptide present in
granule cells and in the terminal fields of the mossy fibres)
[63] (Figure 2D).
The extent of mossy fibre sprouting can vary between
HS cases (Figure 2A–D). The process of sprouting is
thought to be triggered early by both hippocampal seizure
activity [37,64,65] and neuronal loss. There is some evi-
dence that newly generated cells form a significant contri-
bution to mossy fibre sprouting [36,52]. Of note, it is
absent or at the most mild in HS associated with
neurodegeneration and dementia [24]. In TLE patients
with milder degrees of CA4 neuronal loss, mossy fibre
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Figure 2. Axonal sprouting in hippocampal sclerosis (HS)/temporal lobe epilepsy (TLE). Mossy fibre sprouting identified with Timm staining
in hippocampal sclerosis (HS) (A–C). In (A) the black silver granules are mainly confined to the subgranular zone and significant sprouting
into the molecular layer (arrow) is not observed. In (B) there is focal sprouting in the molecular layer (arrow) and in (C) marked sprouting is
shown with a dense band of zinc positive granules in the molecular layer. (D) Similar mossy fibre sprouting confirmed with dynorphin
immunohistochemistry. (E) Extensive sprouting of neuropeptide Y-positive fibres is seen in the dentate gyrus compared with normal pattern
(inset). (F) Sprouting of galanin fibres is shown in the gliotic dentate gyrus from a case with TLE and hippocampal sclerosis. In HS more
intense synaptic pattern of staining was noted in the molecular layer of the dentate gyrus in a series compared with mTLE cases without HS
(M. Thom, unpub. obs.). (G) The myeloarchitecture can appear abnormal in HS with a random arrangement of fibres permeating the dentate
gyrus. (H) Calretinin immunohistochemistry with sprouting fibres through the molecular layer compared with the compact alignment of
fibres embracing the dentate gyrus in the normal hippocampus (shown in inset). (I) Calbindin immunohistochemistry with sprouted fibres
through the molecular layer in HS and loss of the normal expression in the granule cells. In all images the molecular layer is at the top of
each figure and the subgranular zone at the bottom. Bar is equivalent to approximately 50 μm (A, B, C) and 100 μm in others.
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sprouting may be less pronounced [66–68] as well as in
HS with marked granule cell depletion. The molecular
cues initiating or promoting sprouting include a role for
mammalian target of rapamycin (mTOR) pathway activa-
tion; it has been shown that rapamycin administration
reduces both sprouting and seizures experimentally
[69,70] offering a potential novel treatment. There is also
experimental literature to support that suppression of
mossy fibre sprouting, for example with cyclohexamide,
does not ameliorate seizures [71,72]. In addition we have
noted that sprouting remains sustained in elderly patients
at PM with HS, even with spontaneous cessation of seizure
activity for many years [73]. These observations argue
somewhat against a critical role of sprouting in
hippocampal epileptogenesis. Therefore, although mossy
fibre sprouting is a hallmark pathological feature of HS in
epilepsy, any critical physiological contribution underpin-
ning seizure activity remains to be established.
Interneuronal networks in HS
Although the ILAE classification of HS is based on pat-
terns of principal pyramidal cell loss, stereotypical altera-
tions to hippocampal interneuronal cell types also
accompany this process. This has been studied more
extensively in experimental models, where functional
alterations in relation to cellular, network changes and
epileptogenesis, can be directly correlated with histologi-
cal changes to interneuronal groups [74]. GABAergic cell
types more extensively studied in human TLE/HS include
those expressing calcium-binding proteins (calbindin,
parvalbumin and calretinin) (Figures 2H,I and 3).
Interneurones are also classified according to their mor-
phology, localization and their target domain in the
dentate gyrus and CA regions [75,76]. In general they
provide inhibition at the perisomatic or axon-initial
segment of principle pyramidal neurones, for example
parvalbumin-positive interneurones [50], or dendritic
inhibition for single neurones or neuronal groups (includ-
ing other interneurones), for example calretinin and
neuropeptide Y (NPY)-expressing neurones [75,77]. Both
spatial and temporal variation in the vulnerabilities of
specific interneuronal populations in response to seizures,
is noted in experimental models [78].
The predominant qualitative and quantitative change
reported in human HS studies include loss of protein
expression or reduction in interneuronal number
[50,79,80] (Figure 3D–F). Morphological changes
include cell hypertrophy (Figure 3C), abnormal dendritic
projections with altered distribution of spines [81–83]
and axonal sprouting (Figure 2E,F,G,H,I). Axonal sprout-
ing is the most readily demonstrated qualitative
interneuronal change in routine diagnostic practice and
can be a helpful aid, particularly in a fragmented HS
specimen as well as in investigations of the aetiology of
HS in PM samples [24,25,73] (Tables 2 and 3). It is
exemplified in the dentate gyrus with calretinin, where
expansion of the axonal plexus from the inner to the
outer molecular layer may be observed (Figure 2H)
[25,81]. Sprouting of calbindin-positive axonal networks
through the dentate gyrus (Figure 2L) may also be
evident in tissue sections, when unmasked by the loss of
the normal calbindin expression in the dentate granule
cells and dendrites, a common occurrence in HS
(Figure 2C). Increased complexity of parvalbumin-
positive chandelier cells and terminals in the pyramidal
cell layer and the dentate gyrus has also been noted [50]
(Figure 3G). Sprouting of these inhibitory networks is
often observed to parallel sprouting of excitatory net-
works (the mossy fibres) in established HS [24,25,59,73].
Many interneuronal alterations likely represent adaptive
or compensatory responses to seizures but, nevertheless,
may contribute to sustained excitatory/inhibitory imbal-
ances as well as synchronization of local neuronal net-
works [74,84,85]. As yet there is limited information
regarding any differences in interneuronal changes that
characterize ILAE HS subtypes. There is also experimen-
tal evidence, from stereological acquired data, that there
is not necessarily a direct relationship between the extent
of interneuronal loss and the severity of clinical seizures
[86] which would also be important to further explore in
MTLE subtypes in human tissues.
Neuropeptides in HS
Neuropeptides colocalize with inhibitory neurones, are
stored in large dense vesicles and when released, have
longer half-lives than neurotransmitters, thus modulating
neuronal or network activity over longer periods [87]. NPY,
somatostatin, galanin and dynorphin have endogenous
anti-convulsant properties with protective effects against
epilepsy, whereas substance P has a pro-epileptic effect
[87]. Many neuropeptides show high expression in
hippocampal structures, particularly NPY [88]. Experi-
mental studies confirm release and increased synthesis
of NPY and somatostatin following seizures [89–91].
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Figure 3. Interneuronal changes in hippocampal sclerosis in epilepsy (HS). (A) Normal calbindin pattern with labelling of the granule cells
and apical dendrites. (B) Absent or loss of calbindin expression is noted in the basal cells while the dispersed cells are calbindin positive; this
is a common pattern observed in HS with granule cell dispersion. (C) Virtual total loss of calbindin expression in all the granule cells;
residual hilar calbindin-positive neurones as well as in CA1 (inset) can appear hypertrophic and dysmorphic with abnormal processes
extending from the cell body. (D) The sharp transition between the neuronal loss in CA1 and the preserved subicular (SBC) neurones is
illustrated with MAP2 staining. (E) Calbindin labelling in the same case as (D) shows relative loss of interneurones and their arborizations in
the CA1 as with parvalbumin (F). Increased perisomatic labelling and terminals in the dentate gyrus, as with parvalbumin in an HS case.
(G) Complex parvalbumin terminals are seen in the dentate gyrus granule cell layer in HS. Bar is equivalent to approximately 75 μm.
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Reorganization of NPY fibre networks is the best studied
and argued to ‘define’ the epileptogenic hippocampus
[12,67,92]. In the normal hippocampus, NPY-expressing
cells are readily seen in the hilus of CA4 with a dense plexus
of axons in the outer molecular layer, that synapse with
granule cell dendrites [93] (Figure 2E). In HS, loss of NPY
neurones and extensive sprouting and beading of NPY
axons is noted, extending through the granule cell layer
and into the molecular layer [67,92,94] (Figure 3E). This
NPY-sprouting typically parallels mossy fibre sprouting
and is thought to act by blocking the synchronization of
granule cells through these recurrent mossy collaterals
[95]. NPY-sprouting has been reported in other
(non-MTLE) epilepsy syndromes and in the absence of sig-
nificant HS [73] but is significantly less pronounced,
and often absent, in HS associated with dementia/
neurodegeneration [24]; as such it appears to represent
a good histological marker for the epileptogenic
hippocampus [95]. Recently gene therapy studies using
viral vectors to induce hippocampal NPY over-expression
have resulted in decreased seizure frequency and remains
an attractive treatment strategy [96]. In addition, it has
been recently recognized that NPY also regulates
hippocampal neurogenesis, indicating roles beyond seizure
modulation [97] but that may be relevant to cognitive
decline in epilepsy.
Studies of somatostatin-expressing neurones in HS,
similar to NPY, have demonstrated a reduction in cell
number and radial sprouting of fibres in the dentate gyrus
[67,92]. Galanin is a small peptide of 29 amino acids with
high concentrations in the adjacent amygdala [87]. Its
effects in the hippocampus are mediated by receptors
GalR1 and GalR2 [98] where it exerts a presynaptic inhibi-
tory effect on glutamatergic transmission and is another
promising treatment target [99]. Alteration of galanin net-
works and receptor expression in human HS tissues, com-
pared with other neuropeptides, remain less studied
(Figure 2F). Substance P has been shown to have pro-
epileptic effects with increased expression shown in status
epilepticus [87]. Studies of substance-P receptor express-
ing interneurones in HS have been carried out which have
demonstrated a reduction of interneurones in CA1 and the
hilus in addition to increased multipolar cells in the
molecular layer; morphological changes were also noted
including increased complexity of dendritic branches [81]
and synaptic reorganization [100]. These studies all rein-
force the widespread alteration of neuropeptidergic
systems in HS; as endogenous neuromodulators and a
potential new therapeutic option, these systems, including
the distribution of synthesizing neurones and their recep-
tors, is likely to be more extensively studied in the future.
Neurotransmitters in HS
Abnormalities in the regulation of synaptic neuro-
transmission in HS can occur at any level from protein
synthesis, release, to receptor distribution and assembly
and subsequent signalling cascades [101]. Monogenic
epilepsy syndromes commonly involve mutations in ion
channel or neurotransmitter receptor proteins [102].
The genetics of partial epilepsies, including TLE are likely
to be complex [103]; familial forms of TLE with HS are
recognized and some of the candidate genes also involve
ion channels [104] as well as in sporadic TLE [105]. For
example, a recent genome-wide association study has
linked a sodium channel gene cluster of SCN1a in
patients with HS and a history of febrile seizures [106].
On this theme, abnormalities in the expression and dis-
tribution of voltage-dependent potassium channels have
been shown in tissue sections in HS [107] (Figure 4A).
Altered GABAA neurotransmitter receptor expression,
distribution and assembly has also been reported in HS;
these mediate fast postsynaptic inhibition [108], and
alterations are particularly noted in the dentate gyrus
where the granule cells display remarkable plasticity
[109,110]. Extracellular GABA concentration is influ-
enced by the rate of uptake of this neurotransmitter and
altered levels of GABA transporters GAT-1 and GAT-3
have been shown in TLE [111]. The endocannabinoid
system also modulates glutamatergic and GABAergic
synaptic transmission [112] with a proposed role for
seizure potentiation in TLE [113]. In tissue sections of
HS, a decrease in cannabinoid type 1 receptor (CB1) and
CB1 receptor-binding protein mRNA has been observed
[114] but with increased levels associated with
GABAergic fibres in the dentate gyrus [115], suggesting
a primary modulation of GABAergic transmission
(Figure 4B). There is also evidence for a switch from an
inhibitory to excitatory action of GABA in epilepsy
[116,117], mirroring its developmental function. This
change is mediated by altered expression of neuronal
cation-chloride cotransporters (KCC2 and NKCC1) [118].
Changes in the relative expression of NKCC1 and KCC2
in pyramidal cells of hippocampal subfields has been
shown in TLE/HS (Figure 4C) which may contribute to
epileptiform activity [119,120].
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Figure 4. Pathological alterations potentially contributing to epileptogenesis in hippocampal sclerosis (HS). (A) Prominent labelling of
voltage gate potassium channel (KV1.1) in residual neurones in CA1 in hippocampal sclerosis; differences were noted in the patterns of
expression between hippocampal subfields in HS compared with controls (M. Thom, unpub. obs.). (B) Prominent labelling of cannabinoid
receptor is noted in the plexus in the molecular layer of the dentate gyrus in HS. (C) Intense labelling of CA1 neurones with cation-chloride
cotransporter (NKCC) in HS. (D) In some cases of HS in epilepsy, particularly in adult onset cases or in the context of recent encephalitis,
striking reactive and ‘balloon cell’ gliosis can be seen in the granule cell layer with a proportion of these cells showing membranous CD34
staining, mimicking a focal cortical dysplasia (inset). (E) Immunolabelling with isoform GFAP-delta highlights prominent numbers of small
astroglia, particularly in the subgranular zone, in HS. (F) Immunostaining for gap junction protein connexin 43 (Cx43) demonstrated
prominent labelling of astrocytic cells in the subgranular zone and occasionally in the molecular layer in a post-mortem HS case.
(G) Expression of drug transporter protein, p-glycoprotein, is shown on capillaries within hippocampus. (H) Albumin staining demonstrating
focal leakage from small capillary vessels in a case of HS/TLE. (I) Coexpression of vascular endothelial growth factor (VEGF) and hypoxic
inducible factor 1 alpha (HIF1-alpha) is shown in pyramidal neurones in HS. Bar is equivalent to approximately 35 μm (A, B, D, E, I); 60 μm
(C, E, F, H).
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Astroglia and blood brain barrier dysfunction
Gliosis is a striking component of HS with chronic,
fibrillary gliosis in CA1 and a radial gliosis in the dentate
gyrus [43]; gliosis involving CA4 is a less specific finding
for HS, being a common finding in the absence of
neuronal loss. A few case reports of HS have also noted a
more cellular gliosis with CD34-positive ‘balloon cell’ like
astrocytes in the dentate gyrus, reminiscent of those
observed in focal cortical dysplasia (Figure 4D). These
astroglia were associated with striking rarefaction of the
dentate hilus [121] and were also reported arising in HS
following a nonherpetic limbic encephalitis [122] and
may indicate a different aetiology of the HS in epilepsy.
Glial fibrillary acidic protein (GFAP)-delta, a developmen-
tally regulated isoform, highlights small multinucleate
glial cells, particularly in the subgranular zone of the
dentate gyrus which colocalize with nestin in HS
(Figure 4E) and may represent a specific subpopulation of
glia with specific roles in this neurogenic niche [123];
similar glial cell types were also noted in HS associated
with dementia [24].
Over the last decade there has been a trend away from a
‘neurocentric’ focus with more directed investigations
addressing the participation of astrocytes in the causation
of seizures [124]. There is a breadth of astrocytic function
beyond their acting as supporting cells [125]; dysfunc-
tions of many of these processes may be of relevance to
seizures in HS. Evidence for this includes impaired
glutamate clearance by astrocytes and release in HS (via
EAAT1 and EAAT and glutamine synthetase) [126] and
impaired K+ clearance via inwardly rectifying potassium
channels [127]. Astrocytes are extensively coupled via
gap junctions to form a functional syncytium, primarily
expressing connexin 43. There have been conflicting find-
ings, however, regarding the elevation of these proteins in
hippocampal astrocytes in HS [127–129] (Figure 4F).
Abnormalities of the vasculature have been reported in
HS, with proliferation of micro-vessels [130], vascular
endothelial growth factor receptor expression and loss of
blood-brain barrier integrity [131,132]. Vascular leakage
of proteins, including IgG [133] and albumin may con-
tribute to neuronal dysfunction in epilepsy [134]
(Figure 4H). Of note, other studies, demonstrated a
reduced microvasculature in the sclerotic hippocampus
[135,136]. Over-expression of drug transporter proteins
at the blood brain barrier in HS, such as p-glycoprotein
and multidrug resistance-associated proteins, have been
linked to treatment failure in HS, due to facilitated drug
efflux preventing anti-epileptic drugs from reaching their
target neurones [137,138] (Figure 4G).
Aetiology of HS
Initiating insult and genetic susceptibility factors
The aetiology of HS is still controversial and is likely to be
multifactorial. It is widely considered an acquired pathol-
ogy. Alfred Meyer’s seminal hypothesis from the 1950s
proposed that an initiating event, injury or insult [the
initial precipitating injury’ (IPI)], particularly prolonged
febrile convulsions early in life, primed the immature
hippocampus for the subsequent development of HS
[139,140]. Seizures are known to damage the
hippocampus, particularly prolonged seizures and status
epilepticus [141–145]. Experimentally, TLE has been
induced following prolonged febrile seizures [146] and
prospective studies, as the FEBSTAT study have confirmed
HS (as defined by MRI criteria) in a minority of patients
following febrile status epilepticus [147]. However, as
neither status epilepticus, prolonged febrile seizures nor
repetitive generalized or partial seizures inevitably lead to
HS in the majority of cases, there are likely other suscep-
tibility factors. HS is considered a sporadic condition. Rare
pedigrees provide evidence for a common genetic basis for
febrile seizures and MTLE [148–150]. Although genetic
susceptibility determinants to nonfamilial or sporadic HS
have, as yet, not been clearly defined [103,151–153],
ApoEε4 genotype has been associated with increased risk
of bilateral HS [154] and more recently, HS and febrile
seizures were linked by common genetic variation around
SCN1A gene [106].
Seizure-induced neuronal loss
Necrotic or apoptotic neurones are only very occasionally
seen in surgical specimens of HS as evidence of ongoing
neuronal death. It is generally regarded that seizure-
induced neuronal injury and subsequent loss results from
excitotoxic, glutamatergic neurotransmission, excessive
Na+ and Ca2+, resulting in osmolytic stress and cellular
free-radical production, culminating in necrosis of neu-
rones [155]. Molecular studies also support that activa-
tion of apoptotic cell death pathways (mediated by
both intrinsic and extrinsic pathways) contribute to
hippocampal neurone loss [155,156]. Regarding the dis-
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tribution of neuronal loss in HS, subfield specific regula-
tion of microRNAs has been shown following seizures;
these post-transcriptional regulators of gene expression
may be critical for determining cell death pathways [157].
Hypoxic inducible factor 1 alpha (HIF1-alpha) and vascu-
lar endothelial growth factor (VEGF) neuronal induction
has been shown in HS cases at PM, with some evidence of
correlation of seizure activity prior to death [158]
(Figure 4I). HS can be observed in association with a
second seizure-focus or epileptogenic pathology [such as a
low grade tumour/malformation, e.g. dysembryoplastic
neuroepithelial tumour (DNT), cavernoma]; the pattern of
HS is often type 3 in such ‘dual pathologies’ [9] and
mechanisms of this potentially ‘kindled’ hippocampal
neuronal loss may differ from isolated HS. Indeed, in pae-
diatric MTLE/HS series, a higher percentage of cases have
dual pathologies compared with adult surgical series; this
fact, together with hippocampal maturation, may be rel-
evant to different patterns of neuronal loss and dentate
gyrus abnormalities observed between age groups
[159,160]. Mitochondrial dysfunction has also been pro-
posed to play a role in the underlying pathogenesis of HS
[161].
Inflammation
In HS, neuronophagia or focal infiltrates of microglia are
occasional findings. There is evidence to support activa-
tion of both the innate and adaptive immune system, for
example IL-1β and IL-1 receptor upregulation, has been
noted in astrocytes, microglia and neurones in HS, and
intercellular adhesion molecule 1 (ICAM-1) and kallikrein
expression in glia [162,163]. B and T cell infiltrates,
however, are usually inconspicuous in tissue sections and
mainly in a perivascular location [162–165]. Inflamma-
tory pathway activation in human TLE is supported by
gene expression studies [166] and has been argued to be a
driving force in disease progression [167]. There is evi-
dence that inflammation can perpetuate, augment or even
initiate seizures [168,169]. A potential diagnostic pitfall
to consider is that localized active/chronic inflammation
can be seen in the hippocampus in relation to prior inva-
sive depth electrode recordings. However, the presence of
prominent, more widespread inflammation in HS speci-
mens, nevertheless, should always raise the possibility
of an underlying or previous limbic or autoimmune
encephalitis, particularly in adult onset epilepsy cases
[170]. Regarding underlying viral infection in HS, detec-
tion of human Herpes virus 6 infection was frequently
reported in one HS/TLE series [171] but in another was
only identified in patients with a history of a prior episode
of limbic encephalitis [172].
Underlying maldevelopmental template
Hippocampal sclerosis can be observed in association with
generalized or focal malformations of cortical develop-
ment (MCD) as a dual pathology [173] and with focal
cortical dysplasia (FCD) Type IIIa of the temporal lobe
[174]. There has been ongoing debate regarding if a pre-
existing isolated hippocampal developmental abnormality
could precede HS, and predispose to the development of
sclerosis [29,175–178]. A recent MRI study of family
members of patients with TLE and HS confirmed smaller
hippocampal volumes than normal, which may represent
a developmental variant at risk for HS [179]. Indeed
recent genome-wide studies have also linked common
genetic variants which associate with hippocampal
volume [180,181]; further study may identify how these
genes influence hippocampal development and if they are
of relevance to loss of hippocampal volume and vulner-
ability to HS in epilepsy. There is also ongoing debate
regarding the relevance of hippocampal malrotation (also
known as incomplete hippocampal inversion) to epilepsy,
TLE, HS and febrile seizures [182]. In malrotation, the
pyramidal cell layer of the CA1/subiculum region typi-
cally appears preserved but hyper-convoluted. There is no
evidence to support that this necessarily evolves into the
typical picture of HS in patients with epilepsy [183,184]
and there is also a lack of the mossy fibre sprouting, GCD
and interneuronal re-organization that typify HS
[175,183,185].
Studies of HS in PM tissues
Although the bulk of neuropathology research in the past
decades has been carried out on surgical tissue with its
obvious advantages [optimally preserved tissues, homoge-
neous clinical cohorts and access to up-to-date
electroencephalography (EEG) and neuroimaging studies]
we should not neglect the ongoing contribution that
autopsy samples can provide in the study of HS in epilepsy.
Primarily, PM tissues enable comparisons of HS occurring
in epilepsy syndromes other than TLE (also known as sec-
ondary HS [7]), the effects of a lifetime of seizures on the
severity of hippocampal neuronal loss and its associated
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pathology [186], enable study of the bilaterality of HS
[73], the extent of involvement along the entire length of
the hippocampus [25] (Figure 5) and to address degenera-
tion in wider networks that have been implied from quan-
titative MRI studies in TLE [20,187,188], in particular the
amygdala, cortex [189], thalamus [190] and cerebellum
[191]. Neuropathology studies have, from the outset, rec-
ognized that more extensive pathology may accompany
HS [15,21], the hippocampus being the epicentre of a
wider process. Experimental data support widespread
changes occurring following induced seizures [192] which
could equally contribute to epileptogenesis. Involvement of
wide networks has been shown inTLE [193,194] and func-
tional and structural imaging of TLE indicates altered
brain connections or connectome in TLE [195,196]. As
such, in recent years there has been a move away from a
‘hippocampocentric’ view of TLE [197,198] addressing
contribution from other brain regions. The main studies
have investigated (i) electrophysiological evidence to
support origin of seizures from extrahippocampal struc-
tures [199,200]; (ii) if wider disease offers the explanation
for poor outcomes (in terms of seizure-freedom) following
localized surgery; and (iii) if severity (or progression)
of any extrahippocampal pathology correlates with
comorbidities, such as cognitive decline.
The cellular and pathological basis of structural
changes in extrahippocampal regions associated with HS
typically manifests as neuronal loss and gliosis with few
studies exploring the contribution of interneuronal popu-
lations [189,201]. It remains to be established whether
any more extended ‘network’ changes arise as a result of
the same initial insult causing HS, if they are subsequent
to HS through retrograde/anterograde degeneration, or if
they arise independently. In PM series it is also possible to
explore the long-term effects of seizures on the brain and
any predisposition to neurodegenerative disease or accel-
erated ageing processes in HS. It has been observed from
a patient cohort closely followed for decades at the
National Society for epilepsy, Chalfont centre, that
patients with pathology proven HS/TLE at PM were less
likely to go into terminal seizure remission with advanced
age compared with other epilepsies [8]. It has also been
shown in this same PM cohort that accelerated tau accu-
mulation in epilepsy was not associated with the severity
of seizures and was also independent of the presence of
HS but correlated with acquired and accumulative trau-
matic brain injury incurred from frequent seizures [202].
Continued donation of brain tissues from patients with
epilepsy to tissue bank resources [for example the Epi-
lepsy Society Brain and Tissue Bank at University College
London (UCL)] will enable further studies of HS in the
future.
Outcomes and the future
Although, benign forms of TLE and HS exist with infre-
quent and well controlled seizures [203] many patients
with HS are medication-resistant and surgical interven-
tion, following a series of investigations such as imaging,
functional tests and video-EEG [204], may offer the best
treatment option at present. Temporal lobe resection tech-
niques have evolved, specifically with more limited resec-
tions, aiming to preserve function without compromising
seizure outcome. Of the selected patients who undergo
surgical treatments, approximately two-thirds will remain
seizure-free in the first 2–3 years with around 57%
seizure-free outcome at 5 years [6]. The cause for surgical
failure and poor outcomes in a proportion if carefully
selected patients, is as yet, unclear.
In summary, there is accumulating evidence that HS in
epilepsy is likely to be heterogenous in many aspects,
including its aetiology, genetics, epigenetics, networks
involved, patterns of neuronal loss as well as responses to
drugs and surgical treatments [20]. Neuropathology- and
tissue-based studies in the future, are likely to continue to
contribute to the ongoing identification of diagnostic and
prognostic biomarkers as well as to further our under-
standing of the causes and ultimately, the prevention of
this pathology.
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Figure 5. Variability of hippocampal sclerosis (HS) in post-mortem and surgical samples. (A) Surgical hippocampectomy specimens, which
on histological examination correlated to (i) end folium gliosis with no evidence of sclerosis; (ii) ILAE Type 3 HS (end-folium sclerosis);
(iii) ILAE type 2 HS (CA1 predominant sclerosis); and (iv) ILAE type 1 HS (classical hippocampal sclerosis). In all of the images the arrow
indicates the pyramidal cell layer of CA1. (B) A 9.4T MRI image of a post-mortem hippocampus from a patient with longstanding epilepsy
and ILAE type 2 (CA1 predominant pattern) of HS at this level (shown in C in a luxol fast blue/cresyl violet preparation), although in other
levels the pattern was type 1 (classical). The MRI has the ability to identify subfields and white matter tracts and, indistinctly (arrowed), the
dentate gyrus. Improved high fields sequences in the future may be able to identify and define patterns of HS pre-operatively. The MRI image
was provided with courtesy of Dr Sofia Eriksson at the Department of Clinical and Experimental Epilepsy, UCL, Institute of Neurology. (D to
I) Paired sections of hippocampus from one hemisphere labelled with (D to F) GFAP/counterstained with cresyl violet and (G to I) calretinin:
at the level of the subthalamic nucleus (STNc; D, G), lateral geniculate nucleus (LGNc; E, H) and hippocampal tail (F, I). Classical pattern
(ILAE type 1) HS is seen in the anterior levels with sprouting of calretinin-positive fibres visible in the dentate gyrus (arrow) at this low
magnification; in the tail gliosis and neuronal loss is visible in the CA4 region of the hippocampal tail. Bar is equivalent to approximately
3 mm (D to I).
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